retatrutide clinical trial thailand patientsafety #publichealth #healthcareleadership #medicalethics #drugsafety #unapproveddrugs #clinicaltrials #npra #fda #weightlossdrugs #healthawareness TRIUMPH-4: Retatrutide Beat Every Prediction

Mojsov, S., Weir, G

Clinical trial data from the SURMOUNT and SURPASS programs did not show dramatic differences in efficacy between abdominal, thigh, and upper arm injections for the majority of participants

Answer: Retatrutide is a triple agonist, meaning a single molecule engages the GLP-1, GIP, and glucagon receptors simultaneously, combining appetite suppression, improved glucose handling, and direct fat metabolism in one weekly dose

Except as expressly stated above, all products are sold "AS IS" and Norway Peptides disclaims all other warranties, express or implied, including but not limited to implied warranties of merchantability, fitness for a particular purpose, and non-infringement